Nephros Stock Analysis

NEPH Stock  USD 1.67  0.03  1.76%   
Nephros is undervalued with Real Value of 2.44 and Target Price of 4.75. The main objective of Nephros stock analysis is to determine its intrinsic value, which is an estimate of what Nephros is worth, separate from its market price. There are two main types of Nephros' stock analysis: fundamental analysis and technical analysis.
The Nephros stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Nephros' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

Nephros Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The book value of Nephros was now reported as 0.79. The company recorded a loss per share of 0.09. Nephros last dividend was issued on the 10th of July 2019. The entity had 1:9 split on the 10th of July 2019. Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. To find out more about Nephros contact Daron Evans at 201 343 5202 or learn more at https://www.nephros.com.

Nephros Quarterly Total Revenue

3.52 Million

Nephros Investment Alerts

Nephros may become a speculative penny stock
Nephros has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 14.24 M. Net Loss for the year was (1.57 M) with profit before overhead, payroll, taxes, and interest of 8.31 M.
Nephros has a poor financial position based on the latest SEC disclosures
About 13.0% of the company outstanding shares are owned by corporate insiders
Latest headline from finance.yahoo.com: Analysts Expect Nephros, Inc. To Breakeven Soon

Nephros Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nephros previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Nephros Largest EPS Surprises

Earnings surprises can significantly impact Nephros' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-09
2023-06-30-0.05-0.040.0120 
2023-05-10
2023-03-31-0.02-0.03-0.0150 
2024-08-08
2024-06-30-0.01-0.03-0.02200 
View All Earnings Estimates

Nephros Thematic Classifications

In addition to having Nephros stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment Idea
Medical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Nephros Stock Institutional Investors

Shares
Mesirow Fin Investmt Mgmt Intl Equity2024-09-30
13.8 K
Morgan Stanley - Brokerage Accounts2024-09-30
5.4 K
Tower Research Capital Llc2024-09-30
2.8 K
Jpmorgan Chase & Co2024-09-30
221
Ubs Group Ag2024-09-30
121
Bank Of America Corp2024-09-30
96.0
Granite Investment Partners, Llc2024-09-30
0.0
Wells Fargo & Co2024-06-30
0.0
Goss Wealth Management Llc2024-06-30
0.0
Wexford Capital Lp2024-09-30
3.6 M
Vanguard Group Inc2024-09-30
202 K
Note, although Nephros' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nephros Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.61 M.

Nephros Profitablity

The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.14)
Return On Capital Employed(0.16)(0.15)
Return On Assets(0.12)(0.13)
Return On Equity(0.22)(0.23)

Management Efficiency

Nephros has return on total asset (ROA) of (0.0796) % which means that it has lost $0.0796 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1561) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The Nephros' current Return On Tangible Assets is estimated to increase to -0.14. The Nephros' current Return On Capital Employed is estimated to increase to -0.15. As of now, Nephros' Debt To Assets are decreasing as compared to previous years. The Nephros' current Asset Turnover is estimated to increase to 1.13, while Total Assets are projected to decrease to under 7.5 M.
Last ReportedProjected for Next Year
Book Value Per Share 0.72  0.76 
Tangible Book Value Per Share 0.60  0.63 
Enterprise Value Over EBITDA(28.32)(26.90)
Price Book Value Ratio 3.87  3.48 
Enterprise Value Multiple(28.32)(26.90)
Price Fair Value 3.87  3.48 
Enterprise Value30.1 M18.9 M
Effective leadership at Nephros drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin
(0.1)
Profit Margin
(0.09)
Beta
1.193
Return On Assets
(0.08)
Return On Equity
(0.16)

Technical Drivers

As of the 31st of January, Nephros secures the Downside Deviation of 2.6, risk adjusted performance of 0.1202, and Mean Deviation of 1.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nephros, as well as the relationship between them.

Nephros Price Movement Analysis

Execute Study
The output start index for this execution was fourty-four with a total number of output elements of seventeen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Nephros middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Nephros. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Nephros Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nephros insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Nephros Outstanding Bonds

Nephros issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nephros uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nephros bonds can be classified according to their maturity, which is the date when Nephros has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Nephros Predictive Daily Indicators

Nephros intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nephros stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Nephros Forecast Models

Nephros' time-series forecasting models are one of many Nephros' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nephros' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Nephros Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nephros prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nephros shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nephros. By using and applying Nephros Stock analysis, traders can create a robust methodology for identifying Nephros entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.10)(0.10)
Operating Profit Margin(0.10)(0.11)
Net Loss(0.10)(0.10)
Gross Profit Margin 0.53  0.34 

Current Nephros Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nephros analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nephros analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.75Strong Buy2Odds
Nephros current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Nephros analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nephros stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nephros, talking to its executives and customers, or listening to Nephros conference calls.
Nephros Analyst Advice Details

Nephros Stock Analysis Indicators

Nephros stock analysis indicators help investors evaluate how Nephros stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nephros shares will generate the highest return on investment. By understating and applying Nephros stock analysis, traders can identify Nephros position entry and exit signals to maximize returns.
Begin Period Cash Flow3.6 M
Total Stockholder Equity8.4 M
Capital Lease Obligations1.8 M
Property Plant And Equipment NetM
Cash And Short Term Investments4.3 M
Net Invested Capital8.4 M
Cash4.3 M
50 Day M A1.5642
Net Interest Income39 K
Total Current Liabilities2.1 M
Investments-75 K
Interest Expense2000.00
Stock Based Compensation1.1 M
Common Stock Shares Outstanding10.4 M
Free Cash Flow752 K
Other Current Assets132 K
Accounts Payable873 K
Net Debt-2.5 M
Depreciation214 K
Other Operating Expenses15.8 M
Non Current Assets Total3.5 M
Liabilities And Stockholders Equity11.9 M
Home CategoryDomestic
Non Currrent Assets Other86 K

Complementary Tools for Nephros Stock analysis

When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated